Quantcast
Last updated on April 16, 2014 at 4:54 EDT

Latest Zeneca Stories

2014-03-28 12:26:18

DUBLIN, March 28, 2014 /PRNewswire/ -- Dublin - Research and Markets ( http://www.researchandmarkets.com/research/8pl45q/investigation) has announced the addition of the "Investigation Report on China Quetiapine Market, 2009-2018" [http://www.researchandmarkets.com/research/8pl45q/investigation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Schizophrenia is a common mental disorder. As a chronic disease, schizophrenia can...

2014-03-28 12:26:09

DUBLIN, March 28, 2014 /PRNewswire/ -- Dublin - Research and Markets ( http://www.researchandmarkets.com/research/lj5htc/investigation) has announced the addition of the "Investigation Report on China's Esomeprazole Market, 2009-2018" [http://www.researchandmarkets.com/research/lj5htc/investigation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Digestive system disease is one of the most frequently occurring diseases....

2014-03-25 00:21:44

DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/s3kv36/investigation) has announced the addition of the "Investigation Report on China Budesonide Market" [http://www.researchandmarkets.com/research/s3kv36/investigation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Asthma and allergic rhinitis are both very common diseases in the world today. As the global atmosphere...

2014-02-20 16:21:25

Agreement with Biopharmaceutical Leader is Indicative of the Longstanding Value of CAS Products COLUMBUS, Ohio, Feb. 20, 2014 /PRNewswire/ -- Chemical Abstracts Service (CAS), the world's authority for chemical information, announced today a landmark five-year agreement for SciFinder(®), the choice for chemistry research, with AstraZeneca, a leading biopharmaceutical company specializing in the discovery, development, manufacturing and marketing of prescription medicines. The...

2014-02-05 08:30:28

SAN DIEGO, Feb. 5, 2014 /PRNewswire/ -- Ambrx Inc. today announced the appointment of Barry Greene to its board of directors. Mr. Greene has more than 20 years of experience in the healthcare, pharmaceutical and biotechnology industries. He is currently president and chief operating officer of Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), a leader in RNAi therapeutics. The appointment increases Ambrx's board membership to six. "Barry joins Ambrx's board at a very exciting time for...

2014-01-21 23:27:11

“2014 Deep Research Report on Global and China Propofol Industry” and “2014 Deep Research Report on Global And China Nucleotide Industry” are the new research reports added to the online library of DeepResearchReports.com. Dallas, Texas (PRWEB) January 21, 2014 2014 Deep Research Report on Global And China Nucleotide Industry is a professional and in-depth study on the current state of the nucleotide industry in Global and China. The report provides a basic overview of the...

2013-10-08 08:28:16

Niche pharmaceutical and biotechnology firms are being encouraged to take advantage of a revolutionary new online portal designed to help companies of all sizes network, build new contacts and secure new business opportunities DOHA, Qatar, Oct. 8, 2013 /PRNewswire/ -- PharmBioWorld.com was launched in August to meet the demand for a single website to unite specialist companies and individuals working within the pharma and biotech fields. The website has been developed by...

2013-07-16 12:28:02

PRINCETON, N.J., July 16, 2013 /PRNewswire/ -- The stockholders of Omthera Pharmaceuticals, Inc. (NASDAQ: OMTH) (the "Company") voted today at a special meeting of stockholders to adopt the previously announced merger agreement providing for the acquisition of the Company by an affiliate of AstraZeneca PLC. The votes cast by the Company's stockholders in favor of the proposal to adopt the merger agreement represented approximately 88.3 percent of the Company's issued and outstanding...

2013-06-06 08:28:56

CARLSBAD, Calif., June 6, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $6 million payment from AstraZeneca related to continuation of the research collaboration between Isis and AstraZeneca to discover and develop novel antisense therapeutics to treat cancer. In addition to the research collaboration, which includes three cancer targets, Isis and AstraZeneca are developing two antisense drugs, ISIS-AR(Rx) and ISIS-STAT3(Rx), discovered...

2013-05-29 16:25:27

MONTREAL, May 29, 2013 /CNW/ - NEOMED and AstraZeneca announced today the expansion of their strategic partnership, further enabling NEOMED's mission of delivering novel therapeutic solutions for unmet medical needs. AstraZeneca will provide NEOMED access to up to 250,000 high-quality compounds from its small molecule compound library to be used to identify candidate compounds for selected targets. The goal is to identify compounds that could potentially become new medicines for a...